|
COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials
|
09 October 2020 |
|
COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India
|
02 October 2020 |
|
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
|
12 September 2020 |
|
Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause
|
09 September 2020 |
|
Biopharma leaders unite to stand with science
|
08 September 2020 |
|
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
|
01 September 2020 |
|
Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19
|
25 August 2020 |
|
AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine
|
14 August 2020 |
|
COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
|
20 July 2020 |
|
AstraZeneca to supply Europe with up to 400 million doses of Oxford University's vaccine at no profit
|
13 June 2020 |